Roth Capital Raises Price Target on Lemaitre Vascular, Inc. (LMAT) to $14 Following 2Q Earnings
Tweet Send to a Friend
Roth Capital reiterated a Buy rating on LeMaitre Vascular (NASDAQ: LMAT), and raised the price target to $14.00 (from $11.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
